TORONTO, July 14, 2014 - Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, has announced a second closing of its recently announced Series B financing, bringing the total raised in this round to $25.5 million.
In conjunction with this closing, new investor BDC Capital joined as an investor and Dion Madsen, senior managing partner at BDC Capital, will join Xagenic's Board of Directors.
From our archives: MaRS Innovation's lead start-up completes $20 million ...
MaRS Innovation co-partner in pan-Canadian effort to help create up to 20 leading start-up companies
CEBIO International Conference, San Diego – June 25, 2014: BDC Venture Capital and the Accel-Rx Health Sciences Accelerator (Accel-Rx) announced today a collaboration to provide critical seed funding to new and emerging Canadian health sciences companies.
This announcement was covered in TechVibes, PE HUB and BetaKit.
Together, Accel-Rx, BDC Venture Capital, and CDRD Ventures Inc. (CVI) which will provide the initial management to launch Accel-Rx operations, would focus on ...